| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | Human B- and T-lymphoma cells were used as the immunogen for the CD45 antibody cocktail. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
CD45 Antibody Cocktail is a research-use primary antibody intended for detection of CD45 in experimental workflows. It is supplied in Purified format. Key antibody attributes include Mouse, Monoclonal (mouse origin), clone SPM569 + SPM570, isotype Mouse IgG1, kappa. Applications listed for this product include WB, IHC-P. Reported/annotated localization context: Cell surface and cytoplasmic. Species reactivity (as provided): Human.
Key elements and design rationale
- Target: CD45 — selectivity and interpretation should be considered in the context of isoforms, post-translational modifications, and related family members when applicable.
- Format: Purified — format can influence background, multiplexing compatibility, and downstream detection strategies.
- Antibody identity: Mouse, Monoclonal (mouse origin), clone SPM569 + SPM570, isotype Mouse IgG1, kappa — these attributes help align secondary reagents and controls (e.g., isotype-matched controls) with your assay design.
- Localization: Cell surface and cytoplasmic — expected subcellular distribution can guide band/structure interpretation and help flag off-target signal.
-
Product notes (from provided description): CD45, also referred to as CD45R and PTPRC (Protein tyrosine phosphatase receptor type C), has been identified as a transmembrane glycoprotein, broadly expressed among hematopoietic cells. Along with other members of the PTP family, it regulates a number of cellular processes including cell differentiation, growth and mitotic cycle, and is an essential regulator of B- and T-cell antigen receptor-mediated activation.
Multiple isoforms of CD45 are distributed throughout the immune system and arise due to alternative splicing of exons located in the N-terminus. CD45RA contains the A exon and is a naive T-cell marker which may help prevent autoimmune disease. CD45RB contains B and stains most leukemias and lymphomas. CD45RC contains C and stains thymocytes, monocytes and dendritic cells. CD45RO doesn't contain A, B or C and is a marker of activated T-cells that can be used to classify and diagnose and classify lymphomas. This antibody cocktail will bind to all CD45 isoforms. The variation in these isoforms is localized to the extracellular domain, with the intracellular domain being conserved. Antibody to CD45 is useful in differential diagnosis of lymphoid tumors from non-hematopoietic undifferentiated neoplasms.
Where multiple assay formats are possible, align the antibody format, host/isotype, and listed applications with your detection system and controls to support clear interpretation of signal.
Biological background
In this catalog, CD45 is positioned within Immunology & Inflammation, Tumor, Leukemia, Lymphoma research contexts. Localization annotations (e.g., Cell surface and cytoplasmic) can help contextualize expected signal patterns in imaging and fractionation-based readouts. For authoritative gene/protein nomenclature, domains/isoforms, and curated functional annotations, consult resources such as UniProt, NCBI Gene, and Ensembl.
Research relevance and current trends
- Higher-plex and spatially resolved readouts (e.g., multiplex IF/IHC, spatial omics) are increasing demand for well-characterized primary antibodies with clearly stated host/isotype and labeling strategies.
- Genetic perturbation controls (knockout/knockdown) and orthogonal measurements (e.g., RNA vs protein) are commonly used to strengthen target attribution when interpreting antibody-derived signals.
- Reproducibility initiatives emphasize transparent reporting of antibody identity (clone, host, isotype) and experimental context to improve cross-study comparability.
Common research applications
- WB: interpret changes in signal in the context of sample composition, epitope accessibility, and potential isoform/PTM differences across conditions.
- IHC-P: interpret changes in signal in the context of sample composition, epitope accessibility, and potential isoform/PTM differences across conditions.
- Typical workflow themes: Western blot validation, IHC on FFPE tissue, ELISA binding assay, Specificity controls.
- Workflow notes: Validate CD45 by Western blot in cell/tissue lysates (include controls), Detect CD45 by IHC in FFPE tissue sections (optimize antigen retrieval + dilution), Measure binding to CD45 peptide/protein by ELISA with diluti…
When comparing conditions, consistent sample processing and appropriate negative/positive controls support interpretation of qualitative localization differences and quantitative abundance changes.
Notes for experimental interpretation
- Isoforms and post-translational modifications may shift apparent molecular weight or epitope accessibility, especially across cell states or treatments.
- Species and tissue context can affect sequence conservation, expression level, and background binding; predicted reactivity should be verified in your sample.
- Control concepts include isotype-matched controls, secondary-only controls (for indirect detection), and genetic/orthogonal controls (e.g., KO/KD, independent antibodies, or RNA measurements) when feasible.
Monoclonal and polyclonal antibodies can differ in epitope recognition breadth and lot-to-lot characteristics; consider clonality and clone information (when provided) alongside your assay requirements. Conjugated formats may simplify detection but can change background and multiplexing behavior compared with unconjugated primaries.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
